1. Solitary plasmacytoma of bone and asymptomatic multiple myeloma
by Meletios A. Dimopoulos, Lia A. Moulopoulos, Alice Maniatis, and Raymond Alexanian
Blood
Volume 96(6):
September 15, 2000
©2000 by American Society of Hematology

2. Remission and survival in solitary bone plasmacytoma
Remission and survival in solitary bone plasmacytoma.The panel on the left shows the remission time in 61 patients with solitary plasmacytoma of bone treated at the MD Anderson Cancer Center, according to disappearance and persistence of myeloma protein or ...
Remission and survival in solitary bone plasmacytoma.The panel on the left shows the remission time in 61 patients with solitary plasmacytoma of bone treated at the MD Anderson Cancer Center, according to disappearance and persistence of myeloma protein or nonsecretory myeloma. The panel on the right shows cause-specific survival after radiotherapy in the same groups of patients.
Meletios A. Dimopoulos et al. Blood 2000;96:
©2000 by American Society of Hematology

3. Progression of asymptomatic myeloma
Progression of asymptomatic myeloma.The panel on the left shows the variable times to disease progression in 123 asymptomatic patients with multiple myeloma at the MD Anderson Cancer Center, according to risk status defined by the presence of 0, 1, or 2 or ...
Progression of asymptomatic myeloma.The panel on the left shows the variable times to disease progression in 123 asymptomatic patients with multiple myeloma at the MD Anderson Cancer Center, according to risk status defined by the presence of 0, 1, or 2 or more of the following abnormalities: monoclonal protein level above 30 g/L, IgA myeloma protein type, and urinary protein level above 50 mg/day on Bence Jones assessment (P < .01). The panel on the right shows the variable times to disease progression in 43 asymptomatic patients considered at intermediate risk on the basis of magnetic resonance imaging results (P < .01).
Meletios A. Dimopoulos et al. Blood 2000;96:
©2000 by American Society of Hematology